Biotechnology Shares of US biotech Moderna surged 9.3% to $85.87 by close on Thursday, after trial results of its Merck & Co jointly developed experimental cancer vaccine, mRNA-4157, used in conjunction with Merck's Keytruda (pembrolizumab) treatment, showed reduced risk of death or relapse in patients with the most deadly form of skin cancer after three years. 15 December 2023